Your browser doesn't support javascript.
loading
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Kornauth, Christoph; Herbaux, Charles; Boidol, Bernd; Guillemette, Chantal; Caron, Patrick; Mayerhöfer, Marius E; Poulain, Stéphanie; Tournilhac, Olivier; Pemovska, Tea; Chong, Stephen J F; Van der Kouwe, Emiel; Kazianka, Lukas; Hopfinger, Georg; Heintel, Daniel; Jäger, Roland; Raderer, Markus; Jäger, Ulrich; Simonitsch-Klupp, Ingrid; Sperr, Wolfgang R; Kubicek, Stefan; Davids, Matthew S; Staber, Philipp B.
Afiliação
  • Kornauth C; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
  • Herbaux C; Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston.
  • Boidol B; Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna.
  • Guillemette C; Centre Hospitalier Universitaire de Québec - Université Laval and Faculty of Pharmacy, Université Laval, Québec.
  • Caron P; Centre Hospitalier Universitaire de Québec - Université Laval and Faculty of Pharmacy, Université Laval, Québec.
  • Mayerhöfer ME; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna.
  • Poulain S; UMR CANTHER, INSERM 1277-CNRS 9020 UMRS 12. University of Lille, Hematology Laboratory, Biology and pathology center, CHU de Lille, 59000 Lille.
  • Tournilhac O; Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite Clermont Auvergne, EA7453 CHELTER, CIC1405, Clermont Ferrand.
  • Pemovska T; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
  • Chong SJF; Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston.
  • Van der Kouwe E; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
  • Kazianka L; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
  • Hopfinger G; 3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna.
  • Heintel D; 1. Medical Department, Center for Oncology and Hematology, Wilhelminenhospital Vienna, Vienna.
  • Jäger R; Department of Laboratory Medicine, Medical University of Vienna.
  • Raderer M; Department of Medicine I, Division of Oncology, Medical University of Vienna.
  • Jäger U; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
  • Simonitsch-Klupp I; Clinical Department of Pathology, Medical University of Vienna.
  • Sperr WR; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
  • Kubicek S; Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna.
  • Davids MS; Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston.
  • Staber PB; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna. philipp.staber@meduniwien.ac.at.
Haematologica ; 106(8): 2251-2256, 2021 08 01.
Article em En | MEDLINE | ID: mdl-33626863
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Prolinfocítica / Compostos Bicíclicos Heterocíclicos com Pontes Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Prolinfocítica / Compostos Bicíclicos Heterocíclicos com Pontes Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article